1.Anastomosis of Vessels less than 2 mm with the Vascular Clip System Clip Applier.
Jae Won LEE ; Suk Jung CHOO ; Jung Hun OH ; In Chul LEE ; Young Mee KWON ; Yong Jik LEE ; Sang Kwon LEE ; Hyun SONG ; Meong Gun SONG
Journal of Korean Medical Science 2001;16(3):303-308
Sutures may cause endothelial trauma and occlusion. The vascular clip system (VCS) clip applier may minimize endothelial injury. Fourteen carotid arteries of nine adult rabbits were transected and re-anastomosed with either #7-0 polypropylene (Group I, n=8) or VCS clips (Group II, n=6). The animals were sacrificed at 1, 3, 8, 14, and 30 days postoperatively. The operation time and bleeding amount were checked for each anastomosis. Carotid angiograms, photography, H&E staining and scanning electron microscopy (SEM) were performed. Fibrin and thrombus, inflammatory cell infiltration, endothelial disruption, luminal distortion, fibrosis, and wall thickening were compared. The luminal diameter was greater in group II. There were minimal differences in thrombosis, wall thickening and fibrosis between the two groups. However, fibrin, inflammatory cell infiltration, multinucleated giant cell formation, endothelial disruption, and luminal distortion were greater in group I. On SEM, group I showed trans-mural penetration. In contrast, group II showed suture margin eversion and no transmural penetration. Stenosis was greater in group I than in group II on carotid angiogram. The operation time was shorter in group II than in group I, i.e. 5+/-1.4 min vs. 11+/-3.8 min, respectively. The current data showed similar or superior results with VCS clips in comparison to conventional suturing with polypropylene.
Angiography
;
Animal
;
Arteriovenous Shunt, Surgical/*instrumentation/methods
;
Carotid Arteries/pathology/*surgery/ultrastructure
;
Microscopy, Electron, Scanning
;
Rabbits
;
Surgical Stapling/*instrumentation/methods
2.Application of vascular surgery techniques in tumor resection.
Chinese Journal of Surgery 2007;45(3):161-162
3.Validation for access recirculation and access flow rate measurement by contrast-enhanced ultrasonography during hemodialysis.
Xiaoxi SHA ; Ning JIANG ; Wei CAI ; Zhen NI ; Luo YAN ; Yulan PENG ; Lei YU ; Xiang ZHOU
Journal of Biomedical Engineering 2012;29(1):84-88
To evaluate the feasibility and accuracy of contrast-enhanced ultrasonography (CEUS) for the measurement of hemodialysis access recirculation (AR) and access flow rate (Qa), a two pump system was used to simulate access and dialyzer flow. AR and Qa under different conditions, such as reversal connection of dialysis lines and the needle orientation, were compared with each other. The value of access flow and recirculation flow were calculated based on the formulas introduced in this paper, and the correlation and consistency between true flow rate and calculated values were analyzed. The measured R correlated well with true value of flow rate (r = 0.57, P = 0.038, Qa > Qb; r = 0.95, P = 0.001, Qa < Qb). The Bland-altman test showed good agreement between the calculated value based on CEUS and true values. The CEUS can be used as a new advanced technology for AR and Qa measurement.
Arteriovenous Shunt, Surgical
;
Blood Flow Velocity
;
Computer Simulation
;
Contrast Media
;
Humans
;
Kidney Failure, Chronic
;
blood
;
therapy
;
Models, Biological
;
Monitoring, Physiologic
;
instrumentation
;
Regional Blood Flow
;
Renal Dialysis
;
methods
;
Ultrasonography
4.Endovascular Recanalization of a Thrombosed Native Arteriovenous Fistula Complicated with an Aneurysm: Technical Aspects and Outcomes.
Su Yeon AHN ; Young Ho SO ; Young Ho CHOI ; In Mok JUNG ; Jung Kee CHUNG
Korean Journal of Radiology 2015;16(2):349-356
OBJECTIVE: To evaluate the technical aspects and outcomes of endovascular recanalization of a thrombosed native arteriovenous fistula (AVF) complicated with an aneurysm. MATERIALS AND METHODS: Sixteen patients who had a thrombosed AVF complicated with an aneurysm (two radiocephalic and 14 brachiocephalic) were included in this study. Recanalization procedures were performed by mechanical thrombectomy using the Arrow-Trerotola percutaneous thrombectomy device and adjunctive treatments. We evaluated dose of thrombolytic agent, underlying stenosis, procedure time, technical and clinical success, and complications. The primary and secondary patency rates were calculated using the Kaplan-Meier analysis. RESULTS: The thrombolytic agents used were 100000 U urokinase mixed with 500 IU heparin (n = 10) or a double dose of the mixture (n = 6). The thrombi in aneurysms were removed in all but two patients with non-flow limiting residual thrombi. One recanalization failure occurred due to a device failure. Aspiration thrombectomy was performed in 87.5% of cases (n = 14). Underlying stenoses were found in the outflow draining vein (n = 16), arteriovenous anastomosis or juxtaanastomosis area (n = 5), and the central vein (n = 3). Balloon angioplasty was performed for all stenoses in 15 patients. Two patients with a symptomatic central vein stenosis underwent insertion of a stent after balloon angioplasty. Mean procedure time was 116.3 minutes. Minor extravasation (n = 1) was resolved by manual compression. Both technical and clinical success rates were 93.8% (n = 15). The primary patency rates at 3, 6, and 12 months were 70.5%, 54.8%, and 31.3%, respectively. The secondary patency rates at 3, 6, and 12 months were 70.5%, 70.5%, and 47.0%, respectively. CONCLUSION: Thrombosed AVF complicated with an aneurysm can be successfully recanalized, and secondary patency can be prolonged with endovascular treatment.
Aged
;
Aged, 80 and over
;
Aneurysm/complications/*surgery
;
Angioplasty, Balloon
;
Arteriovenous Fistula/*surgery
;
Arteriovenous Shunt, Surgical/adverse effects
;
Constriction, Pathologic/complications
;
Endovascular Procedures
;
Equipment Failure
;
Female
;
Fibrinolytic Agents/therapeutic use
;
Heparin/therapeutic use
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Retrospective Studies
;
Stents/adverse effects
;
Thrombectomy/instrumentation/*methods
;
Thrombosis/etiology/*surgery
;
Urokinase-Type Plasminogen Activator/therapeutic use
;
Vascular Patency
;
Veins